DR. DAVID M.S. SHEIN, M.D.

BRONX, NY

Research Active
Orthopaedic Surgery - Orthopaedic Surgery of the Spine NPI registered 21+ years 7 publications 2003 – 2019 NPI: 1053316836
Length of StayHome Care ServicesIntensive Care Units, NeonatalPulmonary SurfactantsClinical Trials as TopicRespiration, ArtificialGestational AgeRespiratory Distress Syndrome, NewbornBirth WeightNew South WalesProfessional PracticeIntensive Care, NeonatalApgar ScoreAustralian Capital TerritoryDrug Administration Routes

Practice Location

1250 WATERS PL
BRONX, NY 10461-2720

Phone: (718) 450-9955

What does DAVID SHEIN research?

Dr. Shein studies several critical areas in medicine, particularly concerning neonatal care and spinal conditions. His research contributes significantly to how premature infants receive surfactant, a substance that aids in breathing, through less invasive methods, thus shortening their hospital stay. Additionally, he investigates treatments for spinal stenosis, a painful condition affecting the spine, promoting a surgical method that has shown high rates of patient satisfaction. He also explores the effectiveness of artificial discs for degenerative disc disease, helping patients with chronic back pain find relief. Lastly, he delves into the biological mechanisms behind prostate cancer, offering insights that could lead to improved treatment strategies.

Key findings

  • In a study on surfactant methods for premature infants, those using less invasive techniques had an average hospital stay of 48 days compared to 54 days for others, although they required more oxygen support later.
  • In treatment for spinal stenosis, 94.7% of patients treated at one spinal level reported significant pain relief after five years, and satisfaction was 97.4%. At two levels, 100% reported similar improvements.
  • The Aesculap activL Artificial Disc proved to be a safe and effective option for patients with degenerative disc disease, offering an alternative to traditional spinal fusion methods.

Frequently asked questions

Does Dr. Shein study premature infants?
Yes, Dr. Shein researches methods of care for premature infants in neonatal intensive care units, focusing on surfactant administration.
What treatments has Dr. Shein researched for spinal issues?
He investigates surgical options for spinal stenosis and evaluates artificial discs for degenerative disc disease, aiming for effective pain relief.
Is Dr. Shein's work relevant to prostate cancer patients?
Yes, his research on the invasion of prostate cancer cells offers insights that could lead to new and improved treatment strategies for patients.

Publications in plain English

Methods of surfactant administration and early ventilation in neonatal intensive care units in New South Wales and the Australian Capital Territory.

2019

Journal of neonatal-perinatal medicine

Legge NA, Shein D, Callander I

Plain English
This study looked at how surfactant (a substance that helps babies breathe) is given to premature infants in neonatal intensive care units in New South Wales and the Australian Capital Territory. Researchers found that babies who received a less invasive method of surfactant and respiratory care spent more time on a type of support called CPAP and less time on mechanical ventilation, resulting in earlier discharge from the hospital (48 days compared to 54 days). However, these babies also needed more oxygen support at 36 weeks corrected age and more went home on oxygen. Who this helps: This helps doctors and healthcare teams in NICUs improve care for premature infants.

PubMed

Spinal Stenosis in the Absence of Spondylolisthesis: Can Interlaminar Stabilization at Single and Multi-levels Provide Sustainable Relief?

2018

International journal of spine surgery

Abjornson C, Yoon BV, Callanan T, Shein D, Grinberg S +1 more

Plain English
This study looked at a new surgical option, called interlaminar stabilization (ILS), for patients with spinal stenosis who do not have a condition called spondylolisthesis. Researchers followed 116 patients who had either 1 or 2 levels of their spine treated with decompression and ILS, finding that 94.7% of those treated at 1 level and 100% at 2 levels reported significant improvement in leg pain after five years, and 97.4% of patients were satisfied with their outcome. This matters because ILS may provide a longer-lasting solution for managing pain compared to traditional treatment methods that only involve decompression. Who this helps: This helps patients suffering from spinal stenosis who haven’t found relief from other treatments.

PubMed

Daniel Halliday, 'The Ethics of a Smoking License'.

2016

Journal of medical ethics

Shein D

PubMed

Evaluation of Aesculap Implant Systems activl Artificial Disc for the treatment of degenerative disc disease.

2016

Expert review of medical devices

Shein D, Shue J, Girardi F

Plain English
Researchers studied the Aesculap activL Artificial Disc to see how well it works for treating degenerative disc disease, which often causes chronic back pain. They found that this artificial disc is a safe and effective option for patients who are suitable candidates, providing an alternative to traditional spinal fusion. As more long-term data becomes available, it will help understand additional concerns related to this treatment. Who this helps: This benefits patients suffering from degenerative disc disease who are considering surgical options for relief.

PubMed

Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

2008

Neoplasia (New York, N.Y.)

Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET +1 more

Plain English
This study focused on how prostate cancer cells invade the bone, a common site for cancer spread. Researchers found that prostate cancer cells that bind to type I collagen, a major protein in bones, are much more mobile and invasive—up to eight times more active—than those that do not. This is important because it reveals a specific biological pathway that helps explain why prostate cancer often spreads to the bones, potentially leading to new treatment strategies. Who this helps: This research benefits patients with prostate cancer and their doctors by providing insights for better treatment options.

PubMed

Paperless chase.

2004

MGMA connexion

Shein D, Goodwin T

PubMed

Liability for adverse events in direct-to-consumer advertising.

2003

JAMA

Shein D

PubMed

Frequent Co-Authors

N A Legge I Callander Celeste Abjornson Byung-Jo Victor Yoon Tucker Callanan Samuel Grinberg Frank P Cammisa Jennifer Shue Federico Girardi Christopher L Hall

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.